A university in Turkey administrated the first dose of ERUCOV-VAC to a human volunteer Wednesday in phase 2 trials of the locally developed coronavirus vaccine candidate.
A statement from Erciyes University in central Kayseri province said the first dose of the inactive vaccine candidate was administered on Nov. 5, 2020 in phase 1.
The ERUCOV-VAC vaccine is being developed at Erciyes University with support from Turkey's Institutes of Health Administration (TUSEB).
The head of the university, Mustafa Calis, said their trials and efforts towards developing the vaccine in phase 2 continue.
"We hope for the trials in phase 2 to be as successful as they were in phase 1," Calis said in the statement.
Under the phase 2 trials, the vaccine candidate will be administrated to at least 250 human volunteers, the statement added.
On Jan. 14, Turkey kicked off a mass COVID-19 vaccination campaign starting with health care workers.
Since last December, Turkey has imposed curfews on weeknights and weekends to curb the spread of the virus.
Since it first appeared in December 2019, the virus has claimed more than 2.35 million lives in 192 countries and regions.
More than 107.2 million cases have been reported worldwide, with recoveries totaling nearly 60 million, according to figures compiled by US-based Johns Hopkins University.
The US, India and Brazil remain the worst-hit countries in terms of infections.
Anadolu Agency website contains only a portion of the news stories offered to subscribers in the AA News Broadcasting System (HAS), and in summarized form. Please contact us for subscription options.